Olema reports early tumor shrinkage in Phase 1 trial of cancer drug OP-3136

Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  Phase 1 study of OP-3136 showed tumor shrinkage in 13 of 19 evaluable patients across three cancer types, with 3 partial responses in heavily pretreated patients who had exhausted standard treatments.

  Item 8.01: Press Release verify on EDGAR →
• high

  Drug was well-tolerated with no dose-limiting toxicities up to 45 mg daily and no severe adverse events; most common side effect was taste changes (81%), with no treatment discontinuations due to safety issues.

  Item 8.01: Safety Data verify on EDGAR →
• high

  Eleven patients remain on treatment including one for 62 weeks, suggesting potential durability; study enrolled patients with advanced breast cancer, prostate cancer, and lung cancer resistant to prior therapies.

  Item 8.01: Efficacy Signals verify on EDGAR →